600671 Hangzhou Tianmushan Pharmaceutical Enterprise
- 8.89
- +0.39+4.59%
Hangzhou Tianmushan Pharmaceutical Enterprise News
*ST Eye Medicine (600671.SH) announced first-quarter results with a net loss of 9.722,800 yuan
Zhitong Finance App News, *ST Pharmaceutical (600671.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 383.34 million yuan, an increase of 72.25% over the previous year; net loss attributable to shareholders of listed companies was 9.722,800 yuan; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 10.7525 million yuan; basic loss per share.
*ST Eye Medicine (600671.SH): Number of shareholders as of April 10, 2024 is 6545
Gelonghui, April 15丨*ST Eye Medicine (600671.SH) said on an interactive platform that as of April 10, 2024, the number of shareholders was 6,545.
*ST Eye Medicine (600671.SH): Number of shareholders as of January 31, 2024 is 6,659
Gelonghui, Feb. 2丨*ST Eye Medicine (600671.SH) said on an interactive platform that as of January 31, 2024, the number of shareholders was 6,659.
*ST Eye Medicine (600671.SH): Expected net loss of 32.245,500 yuan to 40.245,500 yuan in 2023
Gelonghui announced on January 29丨*ST Eye Medicine (600671.SH) announced that it is expected to achieve net profit attributable to shareholders of listed companies of -40.245,500 yuan to -32.2455 million yuan in 2023. Net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses for the year 2023 is estimated to be 41.134 million yuan to -33.1340 million yuan. According to preliminary estimates by the company's finance department, the company's annual revenue in 2023 is estimated to be RMB 116 million to RMB 126.0 million; it is estimated that the company's 2023 annual deductions and main operations
*ST Eye Medicine (600671.SH): Shareholder Yuanjia Medical voluntarily promises not to reduce the company's shares within 18 months
Gelonghui (600671.SH) announced on November 1, *ST Pharmaceutical () announced that, based on confidence in Tianmu Pharmaceutical's future development prospects and recognition of long-term investment value, Yuanjia Medical, a shareholder holding 12.36% of the company, made a voluntary commitment not to transfer its Tianmu Pharmaceutical shares within the next 18 months from November 1, 2023 (November 1, 2023 to April 30, 2025), including shares added during the commitment period due to capital reserves, distribution of stock dividends, allocations, and additional issuance of shares.
[Instant Analysis of BT Financial Report] *ST Meyao 2023 Interim Report: Debt Ratio Rises, Net Assets Turned Negative, Performance Pressure Increased
*ST Pharmaceutical (stock code: 600671) is a company mainly engaged in pharmaceutical manufacturing, drug distribution, traditional Chinese medicine diagnosis and treatment, and health. Its products include amoxicillin clavulanate potassium tablets, dendrobium officinale health products, etc., and the sales area is mainly concentrated in East China and South China. However, judging from its 2023 interim report, the company is facing some financial pressure. First, judging from the balance ratio, *ST's balance ratio rose from 98.51% at the beginning of the period to 107.47% at the end of the period. This indicates that the company's debt pressure has increased, and its liabilities have exceeded total assets, which makes up the company's operations
*ST Eye Drug (600671.SH): New official seal and contract-specific seal introduced
*ST Eye Drug (600671.SH) issued an announcement. The company is seriously worn and worn due to frequent use of official seals and special contract seals,...
TianMuShan Pharma Elects Chairman
Hangzhou TianMuShan Pharmaceutical Enterprise (SHA:600671) elected Liu Jiayong as chairman during a meeting on Friday. The appointment came weeks after Li Feng resigned as chairman due to personal rea
*ST Eye Medicine (600671.SH): Elects Liu Jiayong as Chairman
*ST Eye Drug (600671.SH) announced that the company will hold its 11th session on October 13, 2023...
*ST Eye Medicine (600671.SH): Appoints Xu Xuyu as the company's general manager (president)
*ST Eye Drug (600671.SH) issued an announcement, was nominated by the company's chairman, and reviewed by the nomination committee of the board of directors...
*ST Eye Drug (600671.SH) released semi-annual results, with a net loss of 23.42 million yuan
*ST Pharmaceutical (600671.SH) disclosed the 2023 semi-annual report. The company achieved 509 revenue during the reporting period...
TianMuShan Pharmaceutical CFO Steps Down
You Jie has stepped down as chief financial officer of Hangzhou TianMuShan Pharmaceutical Enterprise (SHA:600671) due to personal reasons, according to a filing on Monday. General Manager Liu Bo will
*ST Eye Medicine (600671.SH): Yu Jie resigns as Chief Financial Officer due to personal reasons
Gelonghui, August 21丨*ST Eye Medicine (600671.SH) announced that the company's board of directors recently received a written resignation report from Yu Jie, the company's financial director. Yu Jie resigned as the company's financial director due to personal reasons. After his resignation, the company will make separate arrangements. After Yu Jie resigned, before the company appointed a new financial director, in order to ensure the normal development of the company's various tasks, the company designated general manager Liu Bo to temporarily assume the duties of financial director for the period until the new financial director was appointed.
*ST Pharmaceutical (600671.SH): It is proposed to raise an additional capital of 278 million yuan from Huilong Huazeding to supplement liquidity and repay debts
Gelonghui, August 21丨*ST Pharmaceutical (600671.SH) announced that the company plans to issue shares to Qingdao Huilong Huase Investment Co., Ltd. (“Huilong Huase”). The number of shares to be issued is 365.33,54 million shares, and the total capital raised is about 278 million yuan. After deducting related issuance expenses, it is intended to be used by Tianmu Pharmaceutical to supplement liquidity and repay debts.
*ST Pharmaceutical (600671.SH) plans to raise 278 million yuan in shares from Huilong Huaze Ding
*ST Eye Drug (600671.SH) announced a plan to issue A-shares to specific targets in 2023. This time, to...
Optimistic Investors Push Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) Shares Up 25% But Growth Is Lacking
Despite an already strong run, Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) shares have been powering on, with a gain of 25% in the last thirty days. Looking back a bit furth
*ST Eye Drug (600671.SH) and related personnel received a warning letter from the Zhejiang Securities Regulatory Bureau
According to the Zhitong Finance App, *ST Eye Medicine (600671.SH) announced that the company recently received the “Decision on Issuing Warning Letter Measures against Hangzhou Tianmusan Pharmaceutical Co., Ltd. and related responsible persons” (“Warning Letter”) issued by the Zhejiang Regulatory Bureau of the China Securities Regulatory Commission (“Zhejiang Securities Regulatory Bureau”). According to reports, the Zhejiang Securities Regulatory Bureau discovered that the company had the following problems during supervision: 1. The company's reporting of projects under construction in 2020-2022 was incorrect and there was a problem of underrecording depreciation. 2. The company did not promptly disclose the bank account freeze situation. 3. The company did not promptly disclose the holding subsidiary Zhejiang Tianmu Biotech
ST Eye Drops (600671.SH): Net loss of 9.055 million yuan in the first quarter
Gelonhui, April 25, 丨 ST Pharmaceutical (600671.SH) released its first quarter report, with operating income of 22.253 million yuan, a year-on-year decrease of 14.58%, net loss of 9.055 million yuan, net loss of 7.822 million yuan after non-net loss of 7.822 million yuan, and a basic loss of 0.0744 yuan per share.
ST Eye Droplets (600671.SH): Delisting Risk Warnings May Be Implemented
Gelonhui, April 19, 丨 ST Drug (600671.SH) announced that the “2022 Annual Performance Forecast Correction Notice” (Notice No. 2023-019) disclosed by the company on April 20, 2023, expects the company's audited net assets at the end of 2022 to be negative. According to the provisions of section 9.3.2 (2) of the “Shanghai Stock Exchange Stock Listing Rules”, “the audited net assets at the end of the most recent fiscal year were negative, or the net assets at the end of the most recent fiscal year after retroactive restatement were negative”, the company's stock trading may be subject to a delisting risk warning by the Shanghai Stock Exchange.
ST Eye Droplers (600671.SH) appoints You Jie as financial director
According to the Zhitong Finance App, ST Pharmaceutical (600671.SH) issued an announcement. The company held the 16th meeting of the 11th board of directors on April 17, 2023 to deliberate and pass the “Proposal on Appointing the Company's Board Secretary” and the “Proposal on Appointing the Company's Chief Financial Officer”. They were nominated separately by the company's chairman Mr. Li Feng and general manager Mr. Liu Bo, and were reviewed and approved by the board's nomination committee. The company's board of directors agreed to appoint Mr. Hao Yilang as the board secretary; Mr. You Jie is the financial director. The term of office begins on the date of review and approval by the current board of directors until the expiration of the term of the eleventh board of directors.
Analysis
Price Target
No Data
